To date, TVAX®’s approach to cancer immunotherapy has generated extensive preclinical and clinical data demonstrating efficacy against a wide variety of cancer types while at the same time producing very little toxicity compared to other cancer treatment strategies.
The company’s two most advanced clinical programs, TVI-Brain-1 and TVI-Kidney-1, are supported by positive Phase 2 clinical data, as well as extensive preclinical and Phase 1 safety studies.
While the brain and kidney cancer therapies represent the company’s most advanced candidates and clinical programs, TVAX also has safety and proof of concept preclinical and human data in breast, colon, lung, melanoma and ovarian cancer. Furthermore, published literature studies have proven the applicability of the technology to leukemia, as well as pancreatic and prostate cancer.
If you are interested in discussing opportunities for partnering with TVAX, please contact:
Chief Financial Officer